NCT05179694 (TRANSLATE) is a NA clinical trial of Prostate biopsy in Prostate Cancer, sponsored by University of Oxford.

Who is sponsoring NCT05179694?

NCT05179694 is sponsored by University of Oxford.

What drugs are being tested in NCT05179694?

Interventions in NCT05179694: Prostate biopsy.

What condition does NCT05179694 study?

NCT05179694 studies Prostate Cancer.

Is NCT05179694 still recruiting?

NCT05179694 is currently status unknown. Last updated 5 January 2022.

Last reviewed 2022-01-05 · How we verify

NCT05179694: TRANSLATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The TRANSLATE Trial

Status unknown NA Last updated 5 January 2022

What this trial tests

NA trial testing Prostate biopsy in Prostate Cancer in 1,042 participants. Status unknown.

Timeline

3 December 2021

Primary endpoint
31 December 2022

31 October 2023

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	1,042
Start date	3 December 2021
Primary completion	31 December 2022
Estimated completion	31 October 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Prostate biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Oxford

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The TRANSLATE randomised controlled trial aims to evaluate local anaesthetic transperineal biopsy (LATP) versus transrectal ultrasound-guided (TRUS) prostate biopsy, in the evaluation of previously biopsy-naive men being investigated for clinically significant prostate cancer (on the basis of an elevated age-specific PSA, or abnormal digital rectal examination, or MRI-visible lesion). Men under investigation for possible prostate cancer and recruited to TRANSLATE will be randomised to receive either an LATP or TRUS prostate biopsy, with the primary outcome measure being detection of clinically significant prostate cancer (defined as any Gleason pattern 4 disease, i.e. any Gleason Grade Group \>=2 disease). Secondary outcome measures include infection, other complications, tolerability, rate of re-biopsy, detection of clinically insignificant prostate cancer, and a full health economics evaluation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.
Bryant RJ, Marian IR, Williams R, Lopez JF, et al · · 2025 · cited 43× · PMID 40139210 · DOI 10.1016/s1470-2045(25)00100-7
Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trial.
Marian IR, Ooms A, Holmes J, Parkes MJ, et al · · 2024 · cited 4× · PMID 38872174 · DOI 10.1186/s13063-024-08224-4
Statistical analysis plan for the TRANSLATE (TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation of potentially clinically significant prostate cancer) multicentre randomised controlled trial
Marian IR, Ooms A, Holmes J, Parkes MJ, et al · · 2024 · DOI 10.21203/rs.3.rs-3924145/v1

Verify or expand the search:

Other trials of Prostate biopsy

Trials testing the same drug.

NCT07271017 — Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe · Phase 1 · recruiting
NCT07352748 — Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa · active not recruiting
NCT06612047 — Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer · recruiting
NCT06505356 — Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage · NA · enrolling by invitation
NCT05822726 — The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer · NA · unknown

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05179694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05179694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing